What Vardenafil Stada Treats: Main Uses and Benefits

Vardenafil is used in situations involving certain distressing symptoms that interfere with daily functioning. The primary clinical area is relevant for easing symptoms associated with erectile dysfunction (ED) in adult men. This condition is characterized by the symptomatic difficulty of achieving or maintaining a penile erection sufficient for satisfactory sexual activity.

Vardenafil is applied when appropriate to help address symptom clusters that create noticeable physiological strain, such as difficulties achieving and sustaining an erection. Conditions where Vardenafil may be part of symptomatic management include ED arising from general causes, and those associated with systemic conditions like diabetes or following certain pelvic procedures.

“Vardenafil is applied across domains where additional symptomatic support is needed to address the disruptive manifestations of erectile failure.”

This supportive relief helps patients cope more steadily with symptom fluctuations. It is often used during phases when symptoms become more noticeable, providing support that may assist with maintaining functional stability for sexual intimacy and overall well-being.

Quick Fact: Supportive management for Erectile Dysfunction (ED) Symptoms.

Regulatory References

1. European Medicines Agency (EMA) overview

Vardenafil Stada is officially indicated for use only in adult men (ge 18 years of age).

Populations Who Must NOT Use This Medicine (Contraindications)

Official regulatory labeling dictates that Vardenafil Stada is strictly contraindicated in the following individuals or circumstances:

• Patients taking nitrates or nitric oxide donors in any form (due to risk of severe hypotension).
• Patients taking guanylate cyclase (GC) stimulators such as riociguat.
• Patients with severe hepatic impairment (Child-Pugh C) or those requiring renal dialysis.
• Patients with a history of Non-arteritic anterior ischaemic optic neuropathy (NAION).
• Patients with severe cardiovascular disorders (e.g., unstable angina, severe cardiac failure, recent stroke/myocardial infarction) for whom sexual activity is deemed inadvisable.
• Those with known hypersensitivity to vardenafil or any excipients.
• Concomitant use with potent CYP3A4 inhibitors (like ritonavir or indinavir) is contraindicated. Concomitant use with ketoconazole or itraconazole is contraindicated in men over 75 years of age.

Age- and Condition-Related Eligibility

The medicine is not indicated for use in children or women. Use requires caution in men with anatomical deformation of the penis or conditions predisposing to priapism (e.g., multiple myeloma, sickle cell anaemia). Dose adjustments are necessary for men ge 65 years of age and for those with moderate hepatic impairment (Child-Pugh B).

Interactions with other medicines and products

The regulatory interaction profile for Vardenafil is structured around two core safety concerns: the potentiation of cardiovascular effects and significantly altered drug clearance.

Contraindicated Combinations The co-administration of Vardenafil with certain medicinal products is strictly prohibited. This includes Nitrates or Nitric Oxide Donors (such as amyl nitrite) and Guanylate Cyclase Stimulators (e.g., Riociguat), due to a documented, life-threatening risk of severe hypotension. Potent CYP3A4 inhibitors, including the HIV protease inhibitors Ritonavir and Indinavir, are also contraindicated, as they cause a massive and uncontrolled increase in Vardenafil systemic exposure. The use of oral Ketoconazole or Itraconazole is further contraindicated for men over 75 years of age due to heightened exposure risk.

Exposure-Altering Interactions Vardenafil is cleared mainly through the metabolic enzyme CYP3A4. Co-administration with moderate CYP3A4 inhibitors, such as Erythromycin or Clarithromycin, is documented to significantly increase Vardenafil plasma concentrations. Dietary intake of Grapefruit or Grapefruit Juice is also expected to increase Vardenafil levels and should be avoided.

Conditional Restrictions A risk of symptomatic hypotension exists when Vardenafil is combined with Alpha-Blockers. Official regulatory guidance states that co-treatment should only be initiated after a patient is stable on their alpha-blocker regimen. A potential for additive QTc prolongation is also documented when Vardenafil is used with other QTc-prolonging medicinal products. Increased Vardenafil exposure is noted in patients with mild or moderate hepatic impairment.

Vardenafil is a molecule classified as an inhibitor of the enzyme phosphodiesterase type 5 (PDE5). This enzyme is expressed prominently in the smooth muscle tissues of the corpus cavernosum. The primary biochemical function of PDE5 is the hydrolysis of cyclic guanosine monophosphate (cGMP)—an important second messenger that mediates smooth muscle relaxation and vasodilation. Vardenafil exerts its action by competitively binding to the active site on the PDE5 enzyme. This binding prevents the enzymatic breakdown of the cGMP molecule. The specific inhibition of PDE5 results in elevated intracellular levels of cGMP within the smooth muscle cells of the penile arteries and sinusoids. This accumulation of cGMP initiates a downstream signaling cascade leading to local smooth muscle relaxation. The resulting arterial vasodilation allows for an increase in localized blood flow to the corpus cavernosum, mediating the final hemodynamic consequence in the targeted tissue.

Administration Scope

Instruction Classifications (High-Level)

Connection to the Overall Use Protocol

The official instructions establish a non-continuous, event-driven pattern for Vardenafil administration, strictly defining what amount to take (labeled dose range), when to take it (timing before activity, once-daily maximum), and how to take it (form-specific intake conditions). This structure is further constrained by mandated population-specific adjustments that modify the starting dose for older adults and patients on certain concurrent medications.

Vardenafil is a type of medication known as a Phosphodiesterase type 5 (PDE5) inhibitor. It is indicated for the treatment of erectile dysfunction (ED) in adult males. The mechanism involves targeting the PDE5 enzyme, which may assist in the relaxation of blood vessels in the penis, promoting blood flow following sexual stimulation.

Clinical Efficacy and Patient Cohorts

Clinical trials, including randomized, placebo-controlled studies, have been conducted to evaluate the effects of vardenafil on erectile function across various patient groups. Outcomes are typically assessed using standardized tools like the International Index of Erectile Function (IIEF) questionnaire.

• General ED: Studies involving the general population of men with ED have consistently reported improvements in key metrics of erectile function compared to a placebo. These trials typically span 12 weeks or longer.
• Associated Conditions: Research has also explored the use of vardenafil in men with ED who have associated conditions, such as diabetes mellitus or hypertension. Findings suggest that the drug's effect on erectile function may be consistent in these subgroups, irrespective of the use of common concomitant medications for these underlying health issues.

Safety Profile Observed in Research

The safety profile is continually monitored through clinical trials and post-marketing surveillance. The most commonly reported events are generally mild and transient.

Serious, though rare, adverse events reported in association with this class of drugs include sudden visual or hearing loss and priapism (a prolonged erection lasting more than four hours). Any such occurrence requires immediate medical evaluation. The concurrent use of nitrates or nitric oxide donors is contraindicated due to the risk of severe hypotension.

Common questions about Vardenafil Stada (FAQ)

Q: What happens if I miss a dose of Vardenafil?

Vardenafil is a medicine taken only when needed, right before planned sexual activity. According to official product information, since it is not a continuously taken medicine, there are no established instructions for a traditional 'missed dose.' A person would typically take the next dose when needed, maintaining the requirement not to exceed the maximum frequency of one dose per day.

Q: Can women or children use Vardenafil?

Vardenafil is formally indicated only for use in adult men, meaning those aged 18 years and older. Official regulatory documents state that the medicine is not indicated and should not be used in children or in women.

Q: What is the difference between the film-coated tablet and the orally dispersible tablet (ODT)?

The main distinction between the two forms is the way they are administered. The orally dispersible tablets (ODT) are administered by placing them on the tongue and allowing them to dissolve without liquid. Official regulatory labeling also explicitly states that the 10 mg ODT is not interchangeable with the 10 mg film-coated tablet.

Q: Why does my doctor recommend a lower starting dose because I'm over 65?

Regulatory guidance recommends that doctors consider a lower starting dose for men aged 65 years and over. This recommendation is made because official studies have shown that older adults may have increased exposure to the medicine in their system compared to younger adults.

Q: Does Vardenafil help with premature ejaculation?

Vardenafil is an inhibitor of the PDE5 enzyme, and its only official therapeutic indication is for the treatment of erectile dysfunction (ED). The medicine is not indicated for the treatment of premature ejaculation.

Q: What should I do if my erection lasts longer than 4 hours?

A prolonged erection, known as priapism, that lasts more than four hours is classified as a serious, rare adverse event associated with this class of drugs. According to official safety information, any such occurrence should be medically evaluated immediately.

Q: How does Vardenafil work to treat ED?

Vardenafil is a type of medicine called a PDE5 inhibitor. When sexual stimulation occurs, it works by relaxing the smooth muscles of the blood vessels in the penis. This action increases localized blood flow, which helps to facilitate the ability to attain and maintain an erection.

How to Store and Dispose of Vardenafil Stada?

Vardenafil Stada must be stored and disposed of strictly according to the procedures outlined in official regulatory labeling to ensure product integrity and environmental safety.

Official Storage Requirements

No special requirements are generally listed regarding protection from light or moisture for the film-coated tablets. The medicine must not be used past the expiry date (EXP) printed on the carton or blister.

Official Disposal Instructions

Unused or expired Vardenafil Stada must not be thrown away via wastewater or household waste. Instead, the product should be returned to a pharmacist. This measure is specified in regulatory documents to help protect the environment.